Literature DB >> 10725417

The C-terminal third of human respiratory syncytial virus attachment (G) protein is partially resistant to protease digestion and is glycosylated in a cell-type-specific manner.

R García-Beato1, J A Melero.   

Abstract

The soluble form of the human respiratory syncytial virus (HRSV) attachment protein (Gs) was purified from the supernatant of infected cell cultures by immunoaffinity chromatography. Digestion of Gs with proteases and Western blot analysis identified two fragments that were partially resistant to protease degradation. Reactivity with diagnostic monoclonal antibodies located these two fragments in the primary structure of the G molecule. The large fragment spanned the C-terminal third of the G protein whereas the small fragment represented the N-terminal half of the large fragment. Purification of Gs from infected cells (either HEp-2 or M6) followed by protease digestion located host-cell-dependent glycosylation of the G protein in the unique part of the large protease-resistant fragment. The use of HRSV mutants encoding truncated G proteins allowed us to place some of the host-cell-dependent glycosylation differences in a small segment of the G protein. Interestingly, cell-specific glycosylations in the C-terminal half of the large protease-resistant fragment influenced the expression of certain epitopes located in its N-terminal half. These results bear important implications for the three-dimensional structure of the G glycoprotein.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10725417     DOI: 10.1099/0022-1317-81-4-919

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  9 in total

Review 1.  Respiratory syncytial virus (RSV) evades the human adaptive immune system by skewing the Th1/Th2 cytokine balance toward increased levels of Th2 cytokines and IgE, markers of allergy--a review.

Authors:  Yechiel Becker
Journal:  Virus Genes       Date:  2006-10       Impact factor: 2.332

2.  N-glycans of F protein differentially affect fusion activity of human respiratory syncytial virus.

Authors:  G Zimmer; I Trotz; G Herrler
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

Review 3.  Role of sialic acid-containing molecules in paramyxovirus entry into the host cell: a minireview.

Authors:  Enrique Villar; Isabel Muñoz Barroso
Journal:  Glycoconj J       Date:  2006-02       Impact factor: 2.916

4.  Antibodies to the central conserved region of respiratory syncytial virus (RSV) G protein block RSV G protein CX3C-CX3CR1 binding and cross-neutralize RSV A and B strains.

Authors:  Youngjoo Choi; Caleb S Mason; Les P Jones; Jackelyn Crabtree; Patricia A Jorquera; Ralph A Tripp
Journal:  Viral Immunol       Date:  2012-05-02       Impact factor: 2.257

Review 5.  Animal pneumoviruses: molecular genetics and pathogenesis.

Authors:  Andrew J Easton; Joseph B Domachowske; Helene F Rosenberg
Journal:  Clin Microbiol Rev       Date:  2004-04       Impact factor: 26.132

Review 6.  Structural, antigenic and immunogenic features of respiratory syncytial virus glycoproteins relevant for vaccine development.

Authors:  José A Melero; Vicente Mas; Jason S McLellan
Journal:  Vaccine       Date:  2016-09-28       Impact factor: 3.641

Review 7.  The host response and molecular pathogenesis associated with respiratory syncytial virus infection.

Authors:  Christine M Oshansky; Wenliang Zhang; Elizabeth Moore; Ralph A Tripp
Journal:  Future Microbiol       Date:  2009-04       Impact factor: 3.165

Review 8.  Respiratory syncytial virus--a comprehensive review.

Authors:  Andrea T Borchers; Christopher Chang; M Eric Gershwin; Laurel J Gershwin
Journal:  Clin Rev Allergy Immunol       Date:  2013-12       Impact factor: 8.667

9.  Molecular Evolutionary Dynamics of Respiratory Syncytial Virus Group A in Recurrent Epidemics in Coastal Kenya.

Authors:  James R Otieno; Charles N Agoti; Caroline W Gitahi; Ann Bett; Mwanajuma Ngama; Graham F Medley; Patricia A Cane; D James Nokes
Journal:  J Virol       Date:  2016-04-29       Impact factor: 5.103

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.